Melphalan, thalidomide and dexamethasone (DrugBank: Thalidomide, Melphalan, Dexamethasone)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
28 | 全身性アミロイドーシス | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01527032 (ClinicalTrials.gov) | September 2002 | 28/7/2011 | Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis | Risk-adapted Therapy for AL Amyloidosis | Amyloidosis | Drug: melphalan, thalidomide and dexamethasone | FDA Office of Orphan Products Development | NULL | Completed | Phase 2 | NULL |